CN109310766A - 多特异性分子 - Google Patents

多特异性分子 Download PDF

Info

Publication number
CN109310766A
CN109310766A CN201780024999.5A CN201780024999A CN109310766A CN 109310766 A CN109310766 A CN 109310766A CN 201780024999 A CN201780024999 A CN 201780024999A CN 109310766 A CN109310766 A CN 109310766A
Authority
CN
China
Prior art keywords
bdm
molecule
antibody
vld
sequence
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780024999.5A
Other languages
English (en)
Chinese (zh)
Inventor
安东尼·西蒙·罗伯茨
乔治·科普西达斯
迈克尔·罗斯·卢克
菲尔·安东尼·詹宁斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imonius Treatment Ltd
Original Assignee
Imunexus Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2016900708A external-priority patent/AU2016900708A0/en
Application filed by Imunexus Pty Ltd filed Critical Imunexus Pty Ltd
Publication of CN109310766A publication Critical patent/CN109310766A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/76—Albumins
    • C07K14/765—Serum albumin, e.g. HSA
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CN201780024999.5A 2016-02-26 2017-02-27 多特异性分子 Pending CN109310766A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
AU2016900708A AU2016900708A0 (en) 2016-02-26 Multi-specific molecules 1
AU2016900709A AU2016900709A0 (en) 2016-02-26 Multi-specific molecules 2
AU2016900709 2016-02-26
AU2016900708 2016-02-26
PCT/AU2017/050168 WO2017143406A1 (en) 2016-02-26 2017-02-27 Multi-specific molecules

Publications (1)

Publication Number Publication Date
CN109310766A true CN109310766A (zh) 2019-02-05

Family

ID=59685848

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780024999.5A Pending CN109310766A (zh) 2016-02-26 2017-02-27 多特异性分子

Country Status (7)

Country Link
US (4) US20190338013A1 (cg-RX-API-DMAC7.html)
EP (1) EP3419667A4 (cg-RX-API-DMAC7.html)
JP (3) JP7536424B2 (cg-RX-API-DMAC7.html)
CN (1) CN109310766A (cg-RX-API-DMAC7.html)
AU (2) AU2017222700B2 (cg-RX-API-DMAC7.html)
TW (1) TW201734037A (cg-RX-API-DMAC7.html)
WO (1) WO2017143406A1 (cg-RX-API-DMAC7.html)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631576A (zh) * 2019-03-26 2021-11-09 四十七公司 用于治疗癌症的多特异性药剂
CN114981306A (zh) * 2019-11-04 2022-08-30 努玛治疗有限公司 多特异性抗体
CN115698056A (zh) * 2020-04-29 2023-02-03 霍伯生物技术公司 双特异性蛋白

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
WO2018014260A1 (en) 2016-07-20 2018-01-25 Nanjing Legend Biotech Co., Ltd. Multispecific antigen binding proteins and methods of use thereof
WO2018068201A1 (en) 2016-10-11 2018-04-19 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against ctla-4
CN110944651A (zh) 2017-02-08 2020-03-31 蜻蜓疗法股份有限公司 用于自然杀伤细胞激活的多特异性结合蛋白及其治疗癌症的治疗性用途
EP4273258A3 (en) 2017-02-20 2024-01-17 Dragonfly Therapeutics, Inc. Proteins binding her2, nkg2d and cd16
IL270743B2 (en) 2017-05-19 2024-09-01 Wuxi Biologics Shanghai Co Ltd Monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4), compositions containing same and uses thereof
KR20210029298A (ko) * 2017-08-16 2021-03-15 드래곤플라이 쎄라퓨틱스, 인크. Nkg2d, cd16, 및 egfr, ccr4 또는 pd-l1에 결합하는 단백질
SG11202004158QA (en) 2017-12-28 2020-06-29 Nanjing Legend Biotech Co Ltd Single-domain antibodies and variants thereof against tigit
CN111836832A (zh) * 2018-01-08 2020-10-27 南京传奇生物科技有限公司 多特异性抗原结合蛋白及其使用方法
CA3084518A1 (en) 2018-01-15 2019-07-18 Nanjing Legend Biotech Co., Ltd. Single-domain antibodies and variants thereof against pd-1
MX2020008333A (es) 2018-02-08 2020-09-21 Dragonfly Therapeutics Inc Terapia de combinacion del cancer que incluye proteinas de union multiespecificas que activan a las celulas asesinas naturales.
CA3090244A1 (en) 2018-02-08 2019-08-15 Dragonfly Therapeutics, Inc. Antibody variable domains targeting the nkg2d receptor
CN112119093A (zh) 2018-02-20 2020-12-22 蜻蜓治疗公司 结合cd33、nkg2d和cd16的多特异性结合蛋白和使用方法
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CN113164570B (zh) 2018-08-08 2024-05-14 蜻蜓疗法股份有限公司 结合nkg2d、cd16和肿瘤相关抗原的蛋白质
CA3108427A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
BR112021012631A2 (pt) 2018-12-26 2021-12-14 Xilio Dev Inc Anticorpos anti-ctla4 e métodos de uso dos mesmos
US20230002450A1 (en) * 2019-02-18 2023-01-05 Courier Therapeutics, Inc. Bispecific Fusion Protein Using Orthopoxvirus Major Histocompatibility Complex (MHC) Class I-Like Protein (OMCP) and Tumor-Specific Binding Partner
WO2021147857A1 (en) * 2020-01-20 2021-07-29 Wuxi Biologics (Shanghai) Co., Ltd A novel wash buffer solution for affinity chromatography
AU2021268340A1 (en) 2020-05-06 2022-12-08 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and CLEC12A
WO2022081529A1 (en) * 2020-10-12 2022-04-21 Greffex, Inc. Antibody constructs to target t cell responses to sars-cov protein expressing cells, their design and uses
EP4301774A4 (en) 2021-03-03 2025-08-13 Dragonfly Therapeutics Inc METHODS OF TREATING CANCER USING MULTI-SPECIFIC BINDING PROTEINS THAT BIND TO NKG2D, CD16, AND A TUMOR-ASSOCIATED ANTIGEN
US11993657B2 (en) * 2021-03-16 2024-05-28 Jn Biosciences Llc Bifunctional molecules for treatment of immune disorders
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子
CN115078718B (zh) * 2022-07-22 2024-11-12 福建师范大学 一种基于表面增强拉曼技术检测透明质酸酶的方法
KR20250087648A (ko) * 2022-11-09 2025-06-16 리플리겐 코포레이션 친화도 제제

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166697B1 (en) * 1998-03-06 2007-01-23 Diatech Pty. Ltd. V-like domain binding molecules
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
CN101932608A (zh) * 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
CN102227447A (zh) * 2008-10-02 2011-10-26 新兴产品开发西雅图有限公司 Cd86拮抗物多靶点结合蛋白

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000060070A1 (en) * 1999-04-01 2000-10-12 Innogenetics N.V. A polypeptide structure for use as a scaffold
US20100081792A1 (en) * 2001-06-28 2010-04-01 Smithkline Beecham Corporation Ligand
WO2010136485A1 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins
AU2017222700B2 (en) * 2016-02-26 2018-09-27 Imunexus Therapeutics Limited Multi-specific molecules
JP2024543164A (ja) * 2021-11-26 2024-11-19 イミュネクサス・セラピューティクス・リミテッド 細胞表面上の結合ドメイン分子

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166697B1 (en) * 1998-03-06 2007-01-23 Diatech Pty. Ltd. V-like domain binding molecules
WO2008096158A2 (en) * 2007-02-08 2008-08-14 Domantis Limited Antibody single variable domains against serum albumin
CN101932608A (zh) * 2007-11-30 2010-12-29 葛兰素集团有限公司 抗原结合构建体
CN102227447A (zh) * 2008-10-02 2011-10-26 新兴产品开发西雅图有限公司 Cd86拮抗物多靶点结合蛋白
WO2010136492A2 (en) * 2009-05-28 2010-12-02 Glaxo Group Limited Antigen-binding proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
NUTTALL SD等: "Design and expression of soluble CTLA-4 variable domain as a scaffold for the display of functional polypeptides", 《PROTEINS》 *
SIMON E.HUFTONA等: "Development and application of cytotoxic T lymphocyte-associated antigen 4 as a protein scaffold for the generation of novel binding ligands", 《FEBS LETTERS》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113631576A (zh) * 2019-03-26 2021-11-09 四十七公司 用于治疗癌症的多特异性药剂
CN114981306A (zh) * 2019-11-04 2022-08-30 努玛治疗有限公司 多特异性抗体
CN115698056A (zh) * 2020-04-29 2023-02-03 霍伯生物技术公司 双特异性蛋白

Also Published As

Publication number Publication date
AU2019200005A1 (en) 2019-01-24
AU2017222700B2 (en) 2018-09-27
US20210230249A1 (en) 2021-07-29
EP3419667A1 (en) 2019-01-02
JP2024026531A (ja) 2024-02-28
JP7857274B2 (ja) 2026-05-12
JP2022105574A (ja) 2022-07-14
US20190338013A1 (en) 2019-11-07
TW201734037A (zh) 2017-10-01
JP7536424B2 (ja) 2024-08-20
WO2017143406A1 (en) 2017-08-31
US20240182542A1 (en) 2024-06-06
US20210040177A1 (en) 2021-02-11
JP2019510812A (ja) 2019-04-18
EP3419667A4 (en) 2019-10-23
US11345736B2 (en) 2022-05-31
AU2017222700A1 (en) 2018-03-22

Similar Documents

Publication Publication Date Title
US20240182542A1 (en) Multi-Specific Molecules
CN114729041B (zh) 用于治疗多种实体瘤的靶向b7h3(cd276)的高亲和力纳米抗体
CN106999587B (zh) 多价中间表位,中间表位结合抗体及其用途
EP4582449A1 (en) Recombinant humanized monoclonal antibody targeting human gprc5d and application thereof
CN109311979A (zh) Psma和cd3双特异性t细胞接合抗体构建体
CN105777907A (zh) 叶酸受体1抗体与免疫缀合物以及其用途
JP7056858B2 (ja) 新規な組換え型二機能性融合タンパク質、その調製方法および用途
CN102482347A (zh) 修饰抗体组合物及其制备和使用方法
US11912771B2 (en) MAGE-A4 peptide-MHC antigen binding proteins
US20260110113A1 (en) Rabbit-derived antigen binding protein nucleic acid libraries and methods of making the same
JP2021532778A (ja) Psmaに対するヒト化抗体
JP2002517223A (ja) モノクローナル抗体、交叉反応性抗体およびそれを生成する方法
CN117964767B (zh) 抗rage抗体、细胞外囊泡及其制备方法和应用
JP2024100838A (ja) 抗ラムダ骨髄腫抗原(lma)発現がん及び自己免疫障害を処置するlma結合タンパク質
Guo et al. HER2-targeted immunotoxins with low nonspecific toxicity and immunogenicity
WO2023045370A1 (zh) 靶向tigit的单克隆抗体
CN111548417B (zh) EGFRvIII和EGFR的双特异性人源抗体及其应用
JP2023548345A (ja) クリッピング率の低減した抗原結合ドメイン
WO2024123708A1 (en) Broadly neutralizing antibody-templated divalent immunogen vaccines
CN117751146A (zh) Mage-a4肽-mhc抗原结合蛋白
CN117285628A (zh) 抗vista抗体及其应用
CN118725130A (zh) 抗ctla-4/抗tigit双特异性抗体及其应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20210621

Address after: Victoria, Australia

Applicant after: Imonius treatment Ltd.

Address before: Victoria, Australia

Applicant before: Imunexus Pty Ltd.

TA01 Transfer of patent application right